JAY P. SHEPARD - Corporate Board Profile

INOVIO PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2020-03-27	Jay P. Shepard joined our Board in January 2020 and qualifies to serve on our Board as a result of his years of healthcare and financial experience. Mr. Shepard was President and Chief Executive Officer of Aravive, Inc. (formerly Versartis, Inc.) from May 2015 to January 2020 and has served as a member of its board of directors since 2013 and as its Chairman since January 2020. From 2012 until May 2015, Mr. Shepard was an Executive Partner at Sofinnova Ventures, a venture capital firm focused on the healthcare industry, which he joined as an Executive in Residence in 2008. From 2010 to 2012, Mr. Shepard served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique pediatric products utilizing proprietary drug delivery technology that was acquired by Pfizer, Inc. From 2005 to 2007, Mr. Shepard served as President and Chief Executive Officer and a member of the board of directors of Ilypsa, Inc., a biopharmaceutical company pioneering novel non-absorbed polymeric drugs for renal and metabolic disorders that was acquired by Amgen Inc. Mr. Shepard currently serves on the board of directors of Esperion Therapeutics, Inc., a publicly traded pharmaceutical company, and of the Christopher & Dana Reeve Foundation. Within the past five years, Mr. Shepard also served on the boards of directors of the public companies Marinus Pharmaceuticals, Inc. and Durect Corporation. Mr. Shepard holds a B.S. in Business Administration from the University of Arizona.
2021-03-25	Jay P. Shepard joined our Board in January 2020 and qualifies to serve on our Board as a result of his years of healthcare and financial experience. Mr. Shepard was President and Chief Executive Officer of Aravive, Inc. (formerly Versartis, Inc.) from May 2015 to January 2020 and has served as a member of its board of directors since 2013 and as its Chairman since January 2020. From 2012 until May 2015, Mr. Shepard was an Executive Partner at Sofinnova Ventures, a venture capital firm focused on the healthcare industry, which he joined as an Executive in Residence in 2008. From 2010 to 2012, Mr. Shepard served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique pediatric products utilizing proprietary drug delivery technology that was acquired by Pfizer, Inc. From 2005 to 2007, Mr. Shepard served as President and Chief Executive Officer and a member of the board of directors of Ilypsa, Inc., a biopharmaceutical company pioneering novel non-absorbed polymeric drugs for renal and metabolic disorders that was acquired by Amgen Inc. Mr. Shepard currently serves on the board of directors of Esperion Therapeutics, Inc. and Ironwood Pharmaceuticals, and serves as the Chairman of the Christopher & Dana Reeve Foundation. Within the past five years, Mr. Shepard also served on the boards of directors of the public companies Marinus Pharmaceuticals, Inc. and Durect Corporation. Mr. Shepard holds a B.S. in Business Administration from the University of Arizona.
2022-03-25	Jay P. Shepard Age: 63 Director Since: 2020 Vice-Chairman of the Board of Directors The members of the Compensation Committee currently are Wendy L. Yarno (Chair), Ann C. Miller, Jay P. Shepard and Lota S. Zoth. The members of the Nomination and Corporate Governance Committee currently are Simon X. Benito (Chair), Roger D. Dansey, Jay P. Shepard and Wendy L. Yarno. Director Compensation Table Jay P. Shepard Fees Earned or Paid in Cash ($): 99,000 Stock Awards ($): 112,140 Option Awards ($): 124,805 Total ($): 335,945
2023-03-28	Jay P. Shepard Age: 64 Director Since: 2020 Director The members of the Compensation Committee currently are Wendy L. Yarno (Chair), Ann C. Miller, Jay P. Shepard and Lota S. Zoth. The members of the Nomination and Corporate Governance Committee currently are Simon X. Benito (Chair), Roger D. Dansey, Jay P. Shepard and Wendy L. Yarno. Director Compensation Table Jay P. Shepard Fees Earned or Paid in Cash ($): 96,250 Stock Awards ($): 35,910 Option Awards ($): 40,434 Total ($): 172,594
2023-11-28	Directors and Named Executive Officers: Jay P. Shepard
2024-04-11	Jay P. Shepard Age: 65 Director Since: 2020 Mr. Shepard currently serves as a Venture Partner with Catalys Pacific. The members of the Audit Committee currently are Lota S. Zoth (Chair), Simon X. Benito and Jay Shepard. The members of the Nomination and Corporate Governance Committee currently are Simon X. Benito (Chair), Roger D. Dansey, Jay P. Shepard and Wendy L. Yarno. Director Compensation Table Jay P. Shepard Fees Earned or Paid in Cash ($): 78,125 Stock Awards ($): 20,014 Option Awards ($): 21,171 Total ($): 119,310
2025-04-07	Jay P. Shepard, Age: 66, Director. Committees: Audit Committee (Member), Compensation Committee (Member), Nomination and Corporate Governance Committee (Member). Total compensation: $129,841.